What this means
This is a planned study that is still recruiting people, so no results exist yet. It aims to collect basic data on how the body handles these drugs in older adults.
Plain-English summary written by an AI model from the registry listing.
- Status
- Recruiting
- Who can join
- Ages 65–80
- Where
- 1 site, including Texas
The science
- Registered title
- MTOR Inhibitors in Older Adults
- Trial ID
- NCT06727305 ↗
- Phase
- PHASE 1 / PHASE 2
- Study type
- interventional
- Conditions
- Aging
- What is tested
- Sirolimus 0.5 Mg Oral Tablet, Sirolimus 1Mg Oral Tablet, Sirolimus 2 MG Oral Tablet, Everolimus 0.5 MG Oral Tablet, Everolimus 1 MG Oral Tablet, Everolimus 2 MG Oral Tablet
- Sponsor
- University of Texas Southwestern Medical Center
- Ages
- 65 Years to 80 Years
- Dates
- First posted Dec 10, 2024 · updated Jun 25, 2026
Registry summary
Over the past decades, healthcare systems face significant challenges to meet the needs of an aging population due to progressive debility, functional decline and chronic diseases development. While there is a growing appreciation of the potential impact of mTOR inhibitors on slowing aging processes, preventing chronic disease and prolonging healthy lifespan, a major challenge in developing clinical trials to establish the clinical efficacy of mTOR inhibitors is the absence of pharmacokinetics (PK) and pharmacodynamics (PD) data in older adults. The proposed study will provide the foundation for future clinical trials assessing the role of mTOR inhibitors on aging related indications
Sites (1)
- UT Southwestern Medical Center, Dallas, Texas, United States